Optimer Pharmaceuticals Announces Peer. Hospital trials.
Friday, May 2nd, 2008SAN DIEGO--(BUSINESS WIRE)--April 2, 2008 - Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the pamphlet of its Phase 1 clinical trials of OPT-80 in the April 2008 copy of Antimicrobial Agents and Chemotherapy published by the American Society for Microbiology. The article is entitled, "Safety, Tolerance and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers Following Single and Multiple Doses" (AAC April 2008; v. 52: 1391-1395).
The results from these studies abide the situation of OPT-80 as an vocal analysis for Clostridium difficile infection, or CDI. OPT-80 is currently being tested in Phase 3 clinical trials for CDI, also known as Clostridium difficile-associated diarrhea. The dissertation highlights some time ago reported statistics from a Phase 1a single-dose and a Phase 1b multiple-dose irritant of OPT-80 for the curing of CDI. Four lone voiced doses of OPT-80 (100, 200, 300, and 450 mg) were administered to fit volunteers in a double-blinded, placebo-controlled Phase 1a study. In the double-blinded Phase 1b study, salutary subjects were randomized to welcome OPT-80 (150, 300, or 450 mg) or placebo for 10 days.
